Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04386317|
Recruitment Status : Recruiting
First Posted : May 13, 2020
Last Update Posted : August 26, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
REM Behavior Sleep Disorder (RBD) is a sleep disorder causing people to 'act out' their dreams. A high percentage of individuals with idiopathic RBD (iRBD) are known to develop conditions affecting the neurons in the brain such as Parkinson's disease (PD). Based on the increased risk to develop PD, individuals with iRBD are currently considered ideal candidates for therapies that can possibly protects brain cells, due to the critical window of opportunity to intervene early before brain cell loss progresses significantly.
Early changes of PD are associated with a number of symptoms including loss of smell, constipation, anxiety and depression. In addition, early heart and brain abnormalities can be visualized using specialized imaging techniques called 123I-MIBG myocardial scintigraphy (MIBG) and dopamine transporter (DAT) single photon emission computerized tomography (SPECT) respectively. The combined presence of certain symptoms and the use of these imaging techniques are considered early markers of PD in individuals with iRBD.
In this study the investigators want to learn about the effect of treatment with the beta-blocker terazosin on MIBG abnormalities found in iRBD patients at risk to develop PD. The investigators believe that reversing the MIBG abnormality might prelude to a slowing of the neurodegenerative process. This drug is approved by the U.S. Food and Drug Administration (FDA) for Benign Prostatic Hyperplasia (BPH) and Hypertension. However, terazosin is not approved by the FDA in patients with iRBD at risk for PD. The available doses for this drug oral formulations are 1mg, 2 mg, 5mg and 10 mg.
Changes visualized with the MIBG imaging technique will be correlated to the presence and severity of neurological (i.e. tremors, stiffness, slow movements, walking difficulties) and other symptoms associated with PD (i.e. abnormal smell, constipation, depression, color vision abnormalities), as measured by specific clinical scales and exams.
|Condition or disease||Intervention/treatment||Phase|
|REM Sleep Behavior Disorder Pre-motor Parkinson's Disease Symptomatic Parkinson Disease||Drug: Terazosin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease|
|Actual Study Start Date :||November 1, 2020|
|Estimated Primary Completion Date :||December 30, 2025|
|Estimated Study Completion Date :||December 30, 2025|
|Experimental: terazosin therapy||
Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
- Differences in 123I-MIBG reuptake, as measured by early and late Heart to mediastinum (H/M) ratio, and Washout Ration (WR), at 26 weeks of treatment with the adrenergic blocker terazosin [ Time Frame: 26 weeks after medication titration ]
- Incidence of adverse events [ Time Frame: 26 weeks after medication titration ]Safety will be monitored collecting the type and frequency of adverse events, including clinical symptoms
- Heart Rate variability changes from baseline at 26 weeks after study medication titration [ Time Frame: 26 weeks after medication titration ]
- Incidence of abnormal vital signs [ Time Frame: 26 weeks after medication titration ]Changes in vital signs ( Blood pressure and Heart rate)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||25 Years to 85 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female of age between 25 and 85 years at time of enrollment.
- Diagnosis of idiopathic REM sleep behavior disorder (iRBD), established either as 'definite RBD' according to the criteria proposed by the International Classification of Sleep Disorders (ICSD)-2 [AASM, 2005] or 'probable RBD' following a score of 6 or higher in the RBD questionnaire (RBDSQ) [Nomura et al, 2011], with a score of at least 1 in subitems 6.1 to 6.4 of question 6 [Halsband et al, 2018].
At least one of the following:
- Diagnosis of hyposmia, established as a University of Pennsylvania Smell Identification Test (UPSIT) score < 20th percentile for the individual's age group and sex.
- Functional constipation assessed by a scores > 4 on a questionnaire based on modified ROME IV diagnostic criteria.
- Color vision abnormality, as assessed using HRR Pseudoisochromatic Plates, in the absence of congenital dyschromatopsia
- Symptoms of depression, as assessed by a Beck Depression Inventory (BDI) fast screen score >3 or concurrent use of antidepressant medications.
- Abnormal 123I-MIBG myocardial scintigraphy, as defined by a Late H/M ratio < 2.2 and/or a WR >20%, with normal cardiac ejection fraction (LVEF >55%).
- Capacity to give informed consent
- Secondary Parkinsonism, including tardive
- Concurrent dementia defined by a score lower than 22 on the MOCA
- Concurrent severe depression defined by a BDI fast screen score greater than 13
Comorbidites related to SNS hyperactivity
- Heart failure (LVEF< 45%)
- Recent myocardial revascularization (< 12 weeks)
- Hypertension (SBP >150 mmHg or DBP> 100mmHg)
- Chronic Atrial fibrillation
- Concurrent use of Alpha- adrenergic antagonist
- Diabetes mellitus
- Untreated Severe Sleep Apnea; Apnea-Hypopnea Index (AHI) > 30/h.
Contraindication to the use of Terazosin
- Recent myocardial infarction (< 48 h)
- Ongoing angina pectoris
- Cardiogenic shock or prolonged
- Breast feeding
- Current use of Phosphodiesterase type 5 inhibitors: sildenafil (Viagra TM), tadalafil (Cialis TM), or vardenafil (Levitra TM)
- History of Priapism
- Neurogenic orthostatic hypotensiondefiened as symptomatic decrease in BP> 20 mmHg systolic or > 10mmHg diastolic and HR increase < 20bpm on supine to sitting or standing
- Blood pressure less than 110 mmHG systolic at screening or baseline visit
- Use of investigational drugs whitin 30 days before screening
- For female participant, Pregnacy, or plans for child-bearing during study period
- Allergy/hypersenstivity to iodine or study medication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04386317
|Contact: Michele L Gregorio, PhDfirstname.lastname@example.org|
|Contact: Gloria Obialisi, MSemail@example.com|
|United States, California|
|Cedars Sinai Medical Center||Recruiting|
|Los Angeles, California, United States, 90048|
|Contact: Gloria Obialisi|
|Responsible Party:||Michele Tagliati, MD, Professor and Vice Chairman, Director of Movement Disorders, Cedars-Sinai Medical Center|
|Other Study ID Numbers:||
|First Posted:||May 13, 2020 Key Record Dates|
|Last Update Posted:||August 26, 2022|
|Last Verified:||August 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
REM Sleep Behavior Disorder
Parkinson Disease, Secondary
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
REM Sleep Parasomnias
Sleep Wake Disorders
Adrenergic alpha-1 Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs